Aspirin Prescribed at Discharge |
BB481284-30DD-4383-928C-82385BBF1B17 |
2 |
40280381-3D27-5493-013D-4BFBD29A5F66 |
|
Primary PCI Received Within 90 Minutes of Hospital Arrival |
84B9D0B5-0CAF-4E41-B345-3492A23C2E9F |
2 |
40280381-3D27-5493-013D-4BEBA8855DEB |
|
Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival |
909CF4B4-7A85-4ABF-A1C7-CB597ED1C0B6 |
2 |
40280381-3D27-5493-013D-40EC9FCF4A60 |
|
Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver |
E1CB05E0-97D5-40FC-B456-15C5DBF44309 |
1 |
8A4D92B2-37BF-6F1B-0137-CCD612A40D0E |
|
Venous Thromboembolism Prophylaxis |
38B0B5EC-0F63-466F-8FE3-2CD20DDD1622 |
2 |
40280381-3D27-5493-013D-4BE1467A5C5A |
|
Intensive Care Unit Venous Thromboembolism Prophylaxis |
FA91BA68-1E66-4A23-8EB2-BAA8E6DF2F2F |
2 |
40280381-3D27-5493-013D-4BD0BAC05A44 |
|
Venous Thromboembolism Patients with Anticoagulation Overlap Therapy |
6F069BB2-B3C4-4BF4-ADC5-F6DD424A10B7 |
2 |
40280381-3CD1-4954-013C-F32C3AA00C8F |
|
Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram |
BCCE43DD-08E3-46C3-BFDD-0B1B472690F0 |
2 |
40280381-3CD1-4954-013D-12B735B91C26 |
|
Venous Thromboembolism Discharge Instructions |
7FE69617-FA28-4305-A2B8-CEB6BCD9693D |
2 |
40280381-3D27-5493-013D-460F43C16CB7 |
|
Incidence of Potentially-Preventable Venous Thromboembolism |
32CFC834-843A-4F45-B359-8E158EAC4396 |
2 |
40280381-3D27-5493-013D-477B9CFB13AF |
|
Discharged on Antithrombotic Therapy |
42BF391F-38A3-4C0F-9ECE-DCD47E9609D9 |
2 |
40280381-3D27-5493-013D-4DCA4B826AE4 |
|
Anticoagulation Therapy for Atrial Fibrillation/Flutter |
03876D69-085B-415C-AE9D-9924171040C2 |
3 |
40280381-3D61-56A7-013D-61A513F50150 |
|
Thrombolytic Therapy |
2838875A-07B5-4BF0-BE04-C3EB99F53975 |
3 |
40280381-3D61-56A7-013D-694C97DB4155 |
|
Antithrombotic Therapy By End of Hospital Day 2 |
93F3479F-75D8-4731-9A3F-B7749D8BCD37 |
2 |
40280381-3D27-5493-013D-37E60AC03200 |
|
Discharged on Statin Medication |
1F503318-BB8D-4B91-AF63-223AE0A2328E |
2 |
40280381-3D27-5493-013D-380BA9CE367C |
|
Stroke Education |
217FDF0D-3D64-4720-9116-D5E5AFA27F2C |
2 |
40280381-3D61-56A7-013D-8477CE9D700A |
|
Assessed for Rehabilitation |
7DC26160-E615-4CC2-879C-75985189EC1A |
2 |
40280381-3D27-5493-013D-4604D3D76BB8 |
|
Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero |
D78CE034-8288-4012-A31E-7F485A74F2A9 |
3 |
40280381-3D27-5493-013D-4B6C7D1E455D |
|
Elective Delivery |
FD7CA18D-B56D-4BCA-AF35-71CE36B15246 |
2 |
40280381-3D27-5493-013D-4DBF0566683C |
|
Statin Prescribed at Discharge |
EBFA203E-ACC1-4228-906C-855C4BF11310 |
3 |
40280381-3D27-5493-013D-5A665E26122A |
|
Healthy Term Newborn |
FF796FD9-F99D-41FD-B8C2-57D0A59A5D8D |
2 |
40280381-3D27-5493-013D-5C2858EC1933 |
|
Hearing Screening Prior To Hospital Discharge (EHDI-1a) |
0924FBAE-3FDB-4D0A-AAB7-9F354E699FDE |
2 |
40280381-3D61-56A7-013D-891538FB7B05 |
|
Appropriate Testing for Children with Pharyngitis |
BEB1C33C-2549-4E7F-9567-05ED38448464 |
2 |
40280381-3D61-56A7-013E-5D1EF9B76A48 |
|
Controlling High Blood Pressure |
ABDC37CC-BAC6-4156-9B91-D1BE2C8B7268 |
2 |
40280381-3D61-56A7-013E-66BC02DA4DEE |
|
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
E35791DF-5B25-41BB-B260-673337BC44A8 |
2 |
40280381-3D61-56A7-013E-5CD94A4D64FA |
|
Breast Cancer Screening |
19783C1B-4FD1-46C1-8A96-A2F192B97EE0 |
2 |
40280381-3D61-56A7-013E-66A5A5834990 |
|
Cervical Cancer Screening |
42E7E489-790F-427A-A1A6-D6E807F65A6D |
2 |
40280381-3D61-56A7-013E-669CBC034836 |
|
Colorectal Cancer Screening |
AA2A4BBC-864F-45EE-B17A-7EBCC62E6AAC |
2 |
40280381-3D61-56A7-013E-5BFF718B5A57 |
|
Childhood Immunization Status |
B2802B7A-3580-4BE8-9458-921AEA62B78C |
2 |
40280381-3D61-56A7-013E-6224E2AC25F3 |
|
Preventive Care and Screening: Influenza Immunization |
A244AA29-7D11-4616-888A-86E376BFCC6F |
2 |
40280381-3D61-56A7-013E-57F49972361A |
|
Pneumonia Vaccination Status for Older Adults |
59657B9B-01BF-4979-A090-8534DA1D0516 |
2 |
40280381-3D61-56A7-013E-66A79D4A4A23 |
|
Use of Imaging Studies for Low Back Pain |
B6016B47-B65D-4BE0-866F-1D397886CA89 |
3 |
40280381-3D61-56A7-013E-62790FE42CA1 |
|
Diabetes: Eye Exam |
D90BDAB4-B9D2-4329-9993-5C34E2C0DC66 |
2 |
8A4D92B2-39CA-AF4B-0139-D472724E0C46 |
|
Diabetes: Foot Exam |
C0D72444-7C26-4863-9B51-8080F8928A85 |
2 |
40280381-3D61-56A7-013E-5D11ABE068EB |
|
Diabetes: Hemoglobin A1c Poor Control |
F2986519-5A4E-4149-A8F2-AF0A1DC7F6BC |
2 |
8A4D92B2-397A-48D2-0139-9CD4937E6C86 |
|
Hemoglobin A1c Test for Pediatric Patients |
95FB767E-0CB2-4778-B5FF-6BA9A53FA28E |
2 |
40280381-3D61-56A7-013E-61EF9907211D |
|
Diabetes: Urine Protein Screening |
7B2A9277-43DA-4D99-9BEE-6AC271A07747 |
2 |
40280381-3D61-56A7-013E-62ABF5662FFF |
|
Diabetes: Low Density Lipoprotein (LDL) Management |
0DAC1DEC-E011-493B-A281-7C28964872DD |
2 |
40280381-3D61-56A7-013E-5D5B19BF6DFB |
|
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic |
0713EA8F-0E5B-4099-8C7C-DD677280398F |
2 |
8A4D92B2-397A-48D2-0139-C626C0935307 |
|
Appropriate Treatment for Children with Upper Respiratory Infection (URI) |
E455FAC0-F2CB-4074-A351-1E68A90FB7CF |
2 |
40280381-3D61-56A7-013E-5CC8AA6D6290 |
|
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
430FFC53-4122-4421-88CC-2EDD8117BB3C |
2 |
40280381-3D61-56A7-013E-62367B892985 |
|
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
8439F671-2932-4D4C-88CA-EA5FAEACC89A |
2 |
40280381-3D61-56A7-013E-666032B244F7 |
|
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation |
DB9D9F09-6B6A-4749-A8B2-8C1FDB018823 |
2 |
40280381-3D61-56A7-013E-425AD8E9179C |
|
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
50164228-9D64-4EFC-AF67-DA0547FF61F1 |
2 |
40280381-3D61-56A7-013E-57FE7ED437D7 |
|
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
53D6D7C3-43FB-4D24-8099-17E74C022C05 |
2 |
40280381-3D61-56A7-013E-66B2CA294C47 |
|
Falls: Screening for Future Fall Risk |
BC5B4A57-B964-4399-9D40-667C896F31EA |
2 |
40280381-3D61-56A7-013E-62684F542B66 |
|
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment |
60176FBF-BFDC-4892-9C9E-604F206553C8 |
2 |
40280381-3D61-56A7-013E-7BC533A071D3 |
|
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use |
B99AAEF6-7889-4ABA-85FC-5A2B739DD098 |
2 |
40280381-3D61-56A7-013E-658BC7A23C9C |
|
Oncology: Medical and Radiation – Pain Intensity Quantified |
9A0330D0-3D9B-11E1-8634-00237D5BF174 |
2 |
40280381-3D61-56A7-013E-62AF4C523143 |
|
Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients |
8479F6D6-4200-4FD0-9438-30048EBE3E29 |
3 |
40280381-3D61-56A7-013E-6B81E6E455A5 |
|
Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer |
AC639794-CB3F-4F4F-8FA6-680300D5ED4E |
2 |
40280381-3D61-56A7-013E-6ABD73E15076 |
|
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
1635C14D-E612-4FA6-96CD-285361AA7F7B |
3 |
40280381-3D61-56A7-013E-6696AF6E477F |
|
HIV/AIDS: Medical Visit |
F70B2984-AF4A-4072-AE0D-CEC677A7FF8F |
2 |
8A4D92B2-3A00-2A25-013A-407C78A12C20 |
|
Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan |
9A031E24-3D9B-11E1-8634-00237D5BF174 |
3 |
40280381-3E93-D1AF-013E-9F642782222A |
|
Documentation of Current Medications in the Medical Record |
9A032D9C-3D9B-11E1-8634-00237D5BF174 |
3 |
40280381-3E93-D1AF-013E-A36090B72CC8 |
|
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures |
9A0339C2-3D9B-11E1-8634-00237D5BF174 |
2 |
40280381-3D61-56A7-013E-66AE98364ADE |
|
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
39E0424A-1727-4629-89E2-C46C2FBB3F5F |
2 |
40280381-3D61-56A7-013E-846AAE0F021F |
|
Pregnant women that had HBsAg testing |
3BBFC929-50C8-44B8-8D34-82BE75C08A70 |
2 |
40280381-3D61-56A7-013E-7B520EB06BF3 |
|
Depression Remission at Twelve Months |
8455CD3E-DBB9-4E0C-8084-3ECE4068FE94 |
2 |
40280381-3D61-56A7-013E-8698AB2E1E30 |
|
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment |
848D09DE-7E6B-43C4-BEDD-5A2957CCFFE3 |
2 |
40280381-3D61-56A7-013E-5D9034CF7065 |
|
Maternal Depression Screening |
8E6C8479-99FD-4949-B0AD-24FA60FE4201 |
1 |
8A4D92B2-3927-D7AE-0139-366C49F93102 |
|
ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range |
A5E96A45-8132-4E72-BF4F-E8C81DB9E641 |
2 |
40280381-3E93-D1AF-013E-9E3E037E08D6 |
|
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented |
9A033A94-3D9B-11E1-8634-00237D5BF174 |
2 |
40280381-3E93-D1AF-013E-AF14FC6B5642 |
|
Children Who Have Dental Decay or Cavities |
61947125-4376-4A7B-AB7A-AC2BE9BD9138 |
2 |
40280381-3D61-56A7-013E-8F2F5AD054E2 |
|
Closing the referral loop: receipt of specialist report |
F58FC0D6-EDF5-416A-8D29-79AFBFD24DEA |
2 |
40280381-3D61-56A7-013E-7AA509DE6258 |
|
Dementia: Cognitive Assessment |
7C443B9B-1AD1-4467-B527-DEFC445701FF |
2 |
40280381-3D61-56A7-013E-57FA83AF36FA |
|
Functional Status Assessment for Complex Chronic Conditions |
BB9B8EF7-0354-40E0-BEC7-D6891B7DF519 |
3 |
40280381-3E93-D1AF-013E-A49CA9F94008 |
|
Functional Status Assessment for Hip Replacement |
2F291003-3F2F-48AF-BEF9-E5AACB95AC3E |
2 |
40280381-3D61-56A7-013E-8B6A8ACA4A39 |
|
Functional Status Assessment for Knee Replacement |
BE8D9655-1194-46EF-B43E-4B1D0C36AB71 |
2 |
40280381-3D61-56A7-013E-8B8F87F64D63 |
|
HIV/AIDS: RNA Control for Patients with HIV |
E0A07809-7B74-473F-BCC4-1891BE506AAA |
2 |
40280381-3D61-56A7-013E-8AB774D0398A |
|
Hypertension: Improvement in Blood Pressure |
1D8363CE-A529-490B-8C98-9B54AA75DA06 |
3 |
40280381-3E93-D1AF-013E-A4CAFFEF4684 |
|
Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients |
8243EAE0-BBD7-4107-920B-FC3DB04B9584 |
3 |
40280381-3D61-56A7-013D-A31D2B2F57EA |
|
Exclusive Breast Milk Feeding |
7D374C6A-3821-4333-A1BC-4531005D77B8 |
2 |
40280381-3D27-5493-013D-4DC3477E6961 |
|
Median Time from ED Arrival to ED Departure for Admitted ED Patients |
9A033274-3D9B-11E1-8634-00237D5BF174 |
2 |
40280381-3D27-5493-013D-4D86B2B36480 |
|
Median Time from ED Arrival to ED Departure for Discharged ED Patients |
3FD13096-2C8F-40B5-9297-B714E8DE9133 |
3 |
40280381-3D27-5493-013D-61073DA32A30 |
|
Median Admit Decision Time to ED Departure Time for Admitted Patients |
979F21BD-3F93-4CDD-8273-B23DFE9C0513 |
2 |
40280381-3D27-5493-013D-4D8E4DC46570 |
|
Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision |
D09ADD1D-30F5-462D-B677-3D17D9CCD664 |
3 |
40280381-3D27-5493-013D-4B637CFF42A3 |
|
Prophylactic Antibiotic Selection for Surgical Patients |
FEEA3922-F61F-4B05-98F9-B72A11815F12 |
3 |
40280381-3D61-56A7-013D-C5EF46C917F4 |
|
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment |
C3657D72-21B4-4675-820A-86C7FE293BF5 |
2 |
40280381-3D61-56A7-013E-5B2AA3493C42 |
|
Use of High-Risk Medications in the Elderly |
A3837FF8-1ABC-4BA9-800E-FD4E7953ADBD |
2 |
40280381-3D61-56A7-013E-65C9C3043E54 |
|
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents |
0B63F730-25D6-4248-B11F-8C09C66A04EB |
2 |
40280381-3D61-56A7-013E-5D530FD26D47 |
|
Chlamydia Screening for Women |
C9930664-BE3D-4FFE-AE4A-5CF4933ECB89 |
2 |
40280381-3D61-56A7-013E-5D4001866C09 |
|
Use of Appropriate Medications for Asthma |
59E84144-6332-4369-AEBD-03A7899CA3DA |
2 |
40280381-3D61-56A7-013E-6649110743CE |
|
Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) |
80744AE2-DE81-4B16-A71D-69522EB865C5 |
2 |
40280381-3D61-56A7-013E-6B885A105724 |
|
Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control |
500E4792-7F94-4E34-8546-EE71C56FE463 |
3 |
40280381-3F77-75C9-013F-7B481CEA02FD |
|
Anti-depressant Medication Management |
8924F2B3-EC06-4650-B634-D70A53DEE577 |
2 |
40280381-3D61-56A7-013E-7AF612436402 |
|
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication |
703CC49B-B653-4885-80E8-245A057F5AE9 |
3 |
40280381-3D61-56A7-013E-62E052273699 |
|
HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis |
1CDD20DE-5DE9-4759-8A93-31F1F8BAAAA2 |
2 |
40280381-3E93-D1AF-013E-A49F8F204114 |
|
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up |
9A031BB8-3D9B-11E1-8634-00237D5BF174 |
2 |
40280381-3E93-D1AF-013E-D6E2B772150D |
|
Depression Utilization of the PHQ-9 Tool |
A4B9763C-847E-4E02-BB7E-ACC596E90E2C |
2 |
40280381-3D61-56A7-013E-8A3638093344 |
|
Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C) |
0336A17B-7C2A-48FC-A657-E9B04269A4CC |
3 |
40280381-3E93-D1AF-013E-B297A0A15BB5 |
|
Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed |
0A7F0278-A05C-40AA-94A4-70EC44F5C568 |
3 |
40280381-3E93-D1AF-013E-B277EE0A5A46 |
|
Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists |
0B81B6BA-3B30-41BF-A2F3-95BDC9F558F2 |
3 |
40280381-3D61-56A7-013E-8ACBFE873BCB |
|